Reaction
Deafness Bilateral reporting signals
As of the last recalculation, Deafness Bilateral appears in 1,669 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is AMIKACIN (PRR 26.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Amikacin | 35 | 26.1 | 26.2 |
| Nevirapine | 14 | 19.5 | 19.5 |
| Cefuroxime | 15 | 16.5 | 16.5 |
| Bupivacaine | 12 | 16.1 | 16.1 |
| Efavirenz | 13 | 14.6 | 14.7 |
| Gentamicin Sulfate | 17 | 13.5 | 13.6 |
| Gentamicin | 14 | 13.5 | 13.5 |
| Clarithromycin | 36 | 13.3 | 13.4 |
| Azithromycin | 40 | 12.7 | 12.7 |
| Azithromycin Monohydrate | 40 | 12.2 | 12.3 |
| Acetylcysteine | 9 | 12.0 | 12.0 |
| Erythromycin | 17 | 11.4 | 11.4 |
| Azithromycin Dihydrate | 48 | 10.5 | 10.5 |
| Rifampin | 11 | 9.5 | 9.5 |
| Ketoconazole Foam | 11 | 9.3 | 9.3 |
| Ketoconazole Cream, 2% | 11 | 9.3 | 9.3 |
| Cisplatin | 54 | 8.9 | 8.9 |
| Voriconazole | 18 | 7.5 | 7.5 |
| Tobramycin Sulfate | 7 | 7.1 | 7.1 |
| Gefitinib | 5 | 6.9 | 6.9 |
| Linezolid | 16 | 6.8 | 6.8 |
| Tobramycin Solution | 6 | 6.2 | 6.3 |
| Baricitinib | 4 | 5.2 | 5.2 |
| Tobramycin | 9 | 4.7 | 4.7 |
| Ipilimumab | 15 | 4.4 | 4.4 |
| Osimertinib | 7 | 2.7 | 2.7 |
| Abaloparatide | 5 | 2.1 | 2.1 |